Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent
FDA Device Recall #Z-1928-2021 — Class I — April 27, 2021
Recall Summary
| Recall Number | Z-1928-2021 |
| Classification | Class I — Serious risk |
| Date Initiated | April 27, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Quidel Corporation |
| Location | Athens, OH |
| Product Type | Devices |
| Quantity | 29,787 kits (96 results/kit) |
Product Description
Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent
Reason for Recall
In rare situations patients infected with high viral load of SARS CoV 2 may have samples that generate Ct values less than or equal to (d) 5 when certain amplification and detection platforms (thermocyclers) are used. These specimens would be falsely interpreted as negative if target amplification occurs prior to a cycle threshold (Ct) value of 5. There have been no formal complaints of False Negative results with Ct values <5 from Lyra SARS-CoV-2 Assay users.
Distribution Pattern
Worldwide distribution - US Nationwide distribution in the states of AL, CA, CT, DC, FL, ID, IN, MA, MI, MO, NM, NY, OH, SC, TN, TX, WA and the countries of Canada, Saudi Arabia, United Kingdom.
Lot / Code Information
Lot Number: 031620A 031620B 031620C 032320 032420 032720 032820A 032820B 040320 040720 040920 041020 174992 175429 175501 175502 175503 176001 176002 176366 176367 176368 178984 178985 180331 180332 180673 180674 180675 182594 184273 185535 185822 186470 186472 187062 187173 187822 189232 189942 190786 193074 193977
Other Recalls from Quidel Corporation
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2545-2025 | Class II | QuickVue: Dipstick Strep A Test: 50T, REF: 2010... | Jun 17, 2025 |
| Z-1636-2024 | Class II | QUIDEL InflammaDry MMP-9 Test, REF: PRS-ID-20-U... | Mar 5, 2024 |
| Z-1637-2024 | Class II | QUIDEL InflammaDry MMP-9 Test, REF: PRS-ID-20, ... | Mar 5, 2024 |
| Z-1086-2024 | Class II | The Sofia 2 Flu + SARS Antigen FIA employs immu... | Jan 3, 2024 |
| Z-1308-2023 | Class II | MicroVue C1-Inhibitor Plus EIA for measuring th... | Feb 1, 2023 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.